Week in Review: SPECT/CT predicts survival | Neurotheranostics | Women OK with cancer risk data

Dear AuntMinnie Member, 

Nuclear medicine and molecular imaging content were the most highly viewed among our readers last week, making up three of the top four articles. Our most popular story featured research on the combination of SPECT/CT and serum prostate-specific antigen levels for evaluating early patient responses to Pluvicto treatment for prostate cancer. 

Speaking of theranostics, a presentation at last week’s annual American Roentgen Ray Society (ARRS) meeting updated attendees on developments in neurotheranostics – applying theranostics to brain disease. And a recently introduced nuclear medicine bill in Congress has once again generated controversy. 

Other research from ARRS 2025 also produced substantial page views, including our coverage on how to manage high-risk breast lesions, that most women are OK with their mammography data being used to assess cancer risk, how radiologists can help increase utilization of lung cancer screening, how diagnosis of metabolic-associated steatotic liver disease (MASLD) may be influenced by racial and social factors, and that most women under 40 haven’t received breast imaging prior to their breast cancer diagnosis. 

See below for all of our top stories of the week.

1. SPECT/CT predicts overall survival in Pluvicto patients
2. ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
3. ARRS: Most women OK with mammo data used for assessing cancer risk
4. Controversy clouds nuclear medicine bill
5. ARRS: How to handle ‘controversial' high-risk breast lesions
6. AI-assisted brain MRI shows promise for improved glioma care
7. Mammo uptake among veterans on par with nonveterans
8. ARRS: Radiologists can help PCPs boost lung cancer screening rates
9. DL model can aid in diagnosing myocardial ischemia
10. ARRS: MASLD diagnosis may be subject to racial factors
11. Preop MRI fails to deliver results for breast cancer subtype
12. AANS: AI shows accuracy in cancer detection
13. ARRS: Most women under 40 have no imaging before breast cancer diagnosis
14. ARRS: Mobile mammo boosts breast screening, but no-show rate still high

Erik L. Ridley
Editor in Chief
AuntMinnie.com